Frances Verter, PhD

Brookeville, Maryland, United States Contact Info
500+ connections

Join to view profile

Activity

Join now to see all activity

Experience & Education

  • CellTrials.org

View Frances’s full experience

See their title, tenure and more.

or

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Publications

  • Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery

    Frontiers Immunology

    This study summarizes 195 clinical trials of advanced cell therapies targeting COVID-19 that were registered over the two years between January 2020 to December 2021. In addition, this work also analyzed the cell manufacturing and clinical delivery experience of 26 trials that published their outcomes by July 2022. A pooled analysis of the 24 MSC studies found that MSCs provide a relative risk reduction for all-cause COVID-19 mortality of RR=0.63 (95% CI 0.46 to 0.85).

    Other authors
    See publication

  • The first decade of advanced cell therapy clinical trials using perinatal cells (2005–2015)

    Future Medicine

    Aim: The first review of advanced cell therapy trials with perinatal cells. Materials & methods: We compiled 281 clinical trials of advanced cell therapy with perinatal cells that were registered in 2005–2015. Results: The most common cell source in these trials is cord blood, but the cell type that provides the mechanism of action in the majority of trials is mesenchymal stem/stromal cells. We analyze trends among the 15 parameters we compiled for these trials. Conclusion: Advanced cell…

    Aim: The first review of advanced cell therapy trials with perinatal cells. Materials & methods: We compiled 281 clinical trials of advanced cell therapy with perinatal cells that were registered in 2005–2015. Results: The most common cell source in these trials is cord blood, but the cell type that provides the mechanism of action in the majority of trials is mesenchymal stem/stromal cells. We analyze trends among the 15 parameters we compiled for these trials. Conclusion: Advanced cell therapy with perinatal cells is a new field that covers a wide range of diagnoses but where most of the trials are early Phase. Researchers in different countries tend to work with a preferred cell source and cell type.

    Other authors
    See publication

  • Umbilical cord blood donation: public or private?

    Nature Bone Marrow Transplantation

    In this commentary, we review the progress of UCB banking technology; we also analyze the current data on pediatric and adult unrelated UCB, including the recent expansion of interest in transplantation for hemoglobinopathies, and discuss emerging studies on the use of autologous UCB for neurologic diseases and regenerative medicine.

    Other authors
    • Karen Ballen
    • Joanne Kurtzberg
    See publication

  • Lifetime Probabilities of Hematopoietic Stem Cell Transplantation in the U.S.

    Biology of Blood and Marrow Transplantation

    Using national data from 2001-2003, we calculated that the cumulative probability of a person having a stem cell transplant by age 70 is 1 in 217.

    Other authors
    • J.J. Nietfeld
    • Marcelo Pasquini
    • Brent Logan
    • Mary M. Horowitz
    See publication

Honors & Awards

  • NMDP / Be The Match 2011 Lifeline Award

    NMDP / Be The Match

    Dr. Frances Verter of Brookeville, MD, for her commitment to increase awareness about public umbilical cord blood donation through her foundation, Parent's Guide to Cord Blood.

More activity by Frances

View Frances’ full profile

  • See who you know in common
  • Get introduced
  • Contact Frances directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More